company background image
CAMX logo

Camurus OM:CAMX Stock Report

Last Price

SEK 597.00

Market Cap

SEK 34.1b

7D

-0.2%

1Y

14.0%

Updated

30 Jan, 2025

Data

Company Financials +

Camurus AB (publ)

OM:CAMX Stock Report

Market Cap: SEK 34.1b

CAMX Stock Overview

A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. More details

CAMX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth6/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 71.7% below our estimate of its fair value

Earnings are forecast to grow 85.81% per year

Analysts in good agreement that stock price will rise by 24.8%

Risk Analysis

Profit margins (15.8%) are lower than last year (28.5%)


Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
Analyst Price Target
Consensus Narrative from 6 Analysts

Buvidal And Brixadi Expansion To Fuel Revenue Growth And Boost Profit Margins

Key Takeaways Strong R&D pipeline and successful regulatory progress signal future revenue growth from new treatments entering various markets. Robust sales and market expansion, particularly with Buvidal and Brixadi, highlight potential revenue upside and market penetration in significant regions.
View narrative
SEK 745.00
FV
19.9% undervalued intrinsic discount
46.03%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Updated narrative

My Notes

Capture your thoughts, links and company narrative

Camurus AB (publ) Competitors

Swedencare

OM:SECARE

SEK 8.1b

AddLife

OM:ALIF B

SEK 18.2b

BioGaia

OM:BIOG B

SEK 12.1b

Biotage

OM:BIOT

SEK 11.1b

Price History & Performance

Summary of share price highs, lows and changes for Camurus
Historical stock prices
Current Share PriceSEK 597.00
52 Week HighSEK 715.00
52 Week LowSEK 417.40
Beta1.0
1 Month Change5.57%
3 Month Change-0.50%
1 Year Change14.04%
3 Year Change357.82%
5 Year Change487.60%
Change since IPO804.55%

Recent News & Updates

Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark

Dec 07
Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Nov 15
Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 10
Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Recent updates

Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark

Dec 07
Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Nov 15
Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 10
Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

Aug 09
What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Jul 19
Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Jul 12
We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02
Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Apr 19
Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Feb 22
Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Feb 17
With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

Dec 20
Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11
Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22
We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Shareholder Returns

CAMXSE PharmaceuticalsSE Market
7D-0.2%-0.7%1.1%
1Y14.0%-1.4%13.3%

Return vs Industry: CAMX exceeded the Swedish Pharmaceuticals industry which returned -1.4% over the past year.

Return vs Market: CAMX matched the Swedish Market which returned 13.3% over the past year.

Price Volatility

Is CAMX's price volatile compared to industry and market?
CAMX volatility
CAMX Average Weekly Movement5.0%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement5.6%
10% most volatile stocks in SE Market11.7%
10% least volatile stocks in SE Market3.2%

Stable Share Price: CAMX has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: CAMX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991225Fredrik Tibergwww.camurus.com

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.

Camurus AB (publ) Fundamentals Summary

How do Camurus's earnings and revenue compare to its market cap?
CAMX fundamental statistics
Market capSEK 34.05b
Earnings (TTM)SEK 266.21m
Revenue (TTM)SEK 1.69b

131.9x

P/E Ratio

20.8x

P/S Ratio

Is CAMX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAMX income statement (TTM)
RevenueSEK 1.69b
Cost of RevenueSEK 128.76m
Gross ProfitSEK 1.56b
Other ExpensesSEK 1.29b
EarningsSEK 266.21m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)4.53
Gross Margin92.38%
Net Profit Margin15.76%
Debt/Equity Ratio0%

How did CAMX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 18:46
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Camurus AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Oscar Haffen LammBryan Garnier & Co
Alexandru CogutBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB